SureTrader SureTrader
Home > Boards > US Listed > Biotechs >

BrainStorm Cell Therapeutics Inc. (BCLI)

Add BCLI Price Alert      Hide Sticky   Hide Intro
Moderator: early_retirement2
Search This Board:
Last Post: 12/6/2016 2:01:01 PM - Followers: 114 - Board type: Free - Posts Today: 0



BrainStorm Cell Therapeutics (NASDAQ:BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as

  • Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease and Motor Neuron Disease)
    Multiple Sclerosis
    Parkinson’s Disease
    Huntington’s Disease

Our platform technology, NurOwn®, uses proprietary culture conditions to induce mesenchymal stem cells (MSCs) to secrete high levels of neurotrophic factors (NTFs) known to promote the survival of neurons. Our research efforts have shown that these MSC-NTF cells might be an effective tool for battling neurodegenerative diseases.

We believe

  • That delivery of these neurotrophic factors to injured or degenerating neurons can prolong their survival and improve their function.
    That MSCs, which possess beneficial properties including the ability to home to sites of injury and to dampen immune responses, represent the ideal biological delivery system for neurotrophic factors.

MSC-NTF cells have been shown in the laboratory and in animal models of neurodegenerative diseases to have a beneficial effect, and BrainStorm and our academic collaborators have published over 20 papers in leading scientific journals demonstrating NurOwn’s mechanism of action and efficacy. We invite you to view the Technology and Pipeline areas of our website to learn more.

NurOwn® in the Clinic

Human testing of MSC-NTF cells was initiated 2010 in ALS patients, a program that has now advanced to phase 2 clinical trials in the United States and Israel.  We have completed two single-arm clinical trials at Hadassah Medical Center in Jerusalem, in which a total of 26 ALS patients received MSC-NTF cells.  These studies established the safety profile of the cells and provided indications of a treatment benefit.

We recently completed a 48 patient randomized, double-blind, placebo-controlled phase 2 study of MSC-NTF cells at three prestigious academic medical centers in the United States.

NurOwn® has received Fast Track status from the US Food and Drug Administration (FDA) in ALS, and has additionally been granted Orphan Status for ALS by the FDA and the European Medicines Agency (EMA).



BrainStorm has developed a proprietary, stem cell based technology that delivers growth factors that can help neurons live longer at or near the site of injury or damage. We are developing this innovative therapy for the treatment of various neurodegenerative diseases. It has been tested in several animal models for various diseases, and has shown safety and promising signs of efficacy in clinical trials for amyotrophic lateral sclerosis.

Neurodegenerative Diseases and Stem Cell Research

Neurodegenerative diseases such as amyotrophic lateral sclerosis, Parkinson’s disease, Huntington’s disease, Alzheimer’s disease, multiple sclerosis, and many others afflict millions of people around the globe, but for the most part lack effective therapies. The need for therapies that can replace or repair dead, dying, stressed or damaged neurons has naturally led investigators to stem cell-based therapies.

In general, there are two distinct and potentially complimentary approaches to treating neurodegenerative diseases with cellular therapies – stem cells can be used to replace dead, damaged or dying neurons, or can be used to support damaged or dying neurons, through a variety of mechanisms including quieting the immune system and inflammation, secretion of growth factors, and differentiation into glial cells.

The first approach presents some important technical challenges, particularly in neurology – not only must one deliver neurons or cells that will turn into neurons, but one must insure those neurons are in the right place and making the right connections with other neurons in the central and/or peripheral nervous system, or with other tissues like muscle. Mesenchymal stem cells sclerosis, also called mesenchymal stromal cells, or MSCs, are an example of the second approach and have been used by researchers to treat a variety of conditions, including some neurodegenerative diseases.

We have made a major advancement on the use of mesenchymal stem cells with our NurOwn® technology platform.


NurOwn® is a cell therapy platform that builds on the enormous research effort that has gone into developing mesenchymal stem cells (MSCs) as a treatment for human diseases. BrainStorm has taken MSCs a step further in developing a therapy customized for the treatment of neurodegenerative diseases.

Mesenchymal Stem Cells

MSCs are multipotent precursor cells found in many tissues, but most commonly obtained from the bone marrow, adipocytes or placenta. MSCs have been used in human studies since the 1990s, initially to enhance engraftment of bone marrow transplants, but eventually researchers discovered that MSCs are able to tamp down the immune system in a variety of different ways.

This led to their being studied as treatments for a variety of immune and inflammatory diseases, such as graft-versus-host disease, inflammatory bowel disease, rheumatoid arthritis and multiple sclerosis, and have been studied in cardiovascular disease, stroke, kidney disease, and many other areas – indeed there have been hundreds of clinical trials completed or ongoing for MSCs in various conditions. Prochymal® (remestemcel-L) is an MSC product that received conditional approval for the treatment of children with acute, steroid-refractory graft versus host disease in Canada and New Zealand.

How NurOwn® Makes a Better Cell

Where others leave off with MSCs, BrainStorm begins. Our patented NurOwn® technology takes MSCs and, by growing them in proprietary conditions, converts them into biological factories secreting a variety of neurotrophic factors (NTFs). NTFs are growth factors known to support the survival of neurons in a variety of conditions, and in animal models of many neurodegenerative diseases.

The NurOwn® technology was developed in the laboratories of Professor Dani Offen and the late Professor Eldad Melamed, at Tel Aviv University, and has been the subject of many publications. Our NTF-secreting MSCs (or, MSC-NTF cells) are designed specifically to treat neurodegenerative diseases by allowing us to deliver several NTFs at or close to the site of injury.

MSC-NTF cells also possess immunomodulatory characteristics and in some diseases, this may provide another mechanism for the cells providing a benefit. MSC-NTF cells secrete a variety of NTFs including Glial Derived Neurotrophic Factor (GDNF), Brain Derived Neurotrophic Factor (BDNF), Vascular Endothelial Growth Factor (VEGF), and Hepatocyte Growth Factor (HGF). Our cells can protect neurons from toxins and have been effective in animal models of ALS, sciatic nerve injury, Parkinson’s disease, multiple sclerosis, optic nerve ischemia and Huntington’s disease.

Stained cells ntfs

Over 60 patients with amyotrophic lateral sclerosis (ALS) have been treated with NurOwn® in clinical trials conducted in the United States and Israel, establishing an excellent safety and tolerability profile and demonstrating promising signs of efficacy.


Clinical Trials:




SEC Filings:                                             



Company Locations:

United States
Three University Plaza Drive, Suite 320
Hackensack, NJ 07601

12 Bazel Street
POB 10019 Kiryat Aryeh
Petach Tikva
Israel 4900101









All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.

Also, keep in mind that moderators may or may not have a position in said stock. Being a moderator isn't a sign of endorsement.

Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement:


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
BCLI News: Current Report Filing (8-k) 09:01 AM
BCLI News: Current Report Filing (8-k) 12/05/2016 06:06:59 AM
BCLI News: Notice of Effectiveness (effect) 11/22/2016 06:01:08 AM
BCLI News: Initial Statement of Beneficial Ownership (3) 11/16/2016 04:40:49 PM
BCLI News: Securities Registration: Employee Benefit Plan (s-8) 09/20/2016 05:02:05 PM
News News Alert: Current Report Filing (8-k) 12/09/2016 09:01:42 AM
#2268   INVESTOR CALL UPDATE: early_retirement2 12/06/16 02:01:00 PM
#2267   correction - they haven't been totally silent. early_retirement2 11/30/16 10:51:19 AM
#2266   unfortunately, it's been pretty silent from the company early_retirement2 11/30/16 10:43:14 AM
#2265   Does anyone know what the progress is with yaman18 11/22/16 01:54:21 PM
#2264   Patent News early_retirement2 10/31/16 09:38:03 AM
#2263   Correction "otherwise I COULDN'T live with myself knowing I early_retirement2 09/16/16 10:21:47 AM
#2262   Longtrailer - thanks for the info. I early_retirement2 09/16/16 10:18:54 AM
#2261   From Zacks report 8/25/2016 longtrailer 09/15/16 01:19:09 PM
#2260   Thanks Early, but the credit should go to longtrailer 09/02/16 04:56:42 PM
#2259   wow great stuff, thanks for sharing. early_retirement2 09/02/16 04:23:11 PM
#2258   Optimistic results for Phase ALS treatment at Jerusalem hospital longtrailer 09/02/16 04:01:47 PM
#2256   Yes, interesting read. Also an interesting read is MasterSalix 08/18/16 09:20:33 AM
#2255   Good read: early_retirement2 08/18/16 09:11:10 AM
#2254   anyone care to speculate as to what the early_retirement2 08/04/16 03:51:06 PM
#2253   You are so nice and kind for the Anti Spinner 07/27/16 09:39:39 AM
#2252   Great! Good luck with that, buddy! MasterSalix 07/27/16 05:35:10 AM
#2251   Your post gives me a "BUY" signal buddy! Anti Spinner 07/27/16 02:00:35 AM
#2250   Good luck to you too. Hope you make MasterSalix 07/24/16 11:13:32 AM
#2249   I was commenting on the reaction of traders early_retirement2 07/24/16 11:09:22 AM
#2248   Something fishy about this stock and co. always MasterSalix 07/21/16 02:31:26 PM
#2247   this is funny, the company releases great results early_retirement2 07/21/16 11:20:47 AM
#2246   * * $BCLI Video Chart 07-18-16 * * ClayTrader 07/18/16 05:25:35 PM
#2245   They are world class. They have produced "world Manaman 07/18/16 04:26:05 PM
#2244   research salaries being paid out here moneymaker248 07/18/16 10:43:17 AM
#2243   Man...that was a good shares robbing! This is Anti Spinner 07/18/16 10:26:20 AM
#2242   BrainStorm Announces Positive Top Line Results from the midastouch017 07/18/16 08:43:07 AM
#2241   Bought in today. Did my DD and I longtrailer 07/15/16 04:21:25 PM
#2240   it's already "cheap" relative to the potential upside. early_retirement2 07/15/16 10:23:04 AM
#2239   In $3.22 long ClearlyStocks 07/15/16 10:14:24 AM
#2238   Was I right? God Bless those Israelis!! ddbl_our_buck 07/15/16 09:49:25 AM
#2237   You really think they are going to have iateclube 07/15/16 08:20:52 AM
#2236   Gonna short it huge this is going down Traderlife 07/14/16 08:58:24 PM
#2235   If we bash it we can load cheap Traderlife 07/14/16 08:57:30 PM
#2234   Hahaha nah dude. Been waiting over a year MikeD248 07/14/16 08:56:06 PM
#2233   Dude go away with your stupid post. Brainstorm early_retirement2 07/14/16 07:55:13 PM
#2232   MAJOR SCAM HERE OFFERING COMING TOMORROW 2.00 PER Traderlife 07/14/16 03:53:43 PM
#2231   Worth a read as we approach results from murocman 07/04/16 09:00:15 AM
#2230   Looking forward to seeing the PH II results murocman 07/02/16 06:17:20 PM
#2229   Been in for over a year. The clinical MikeD248 06/29/16 07:42:43 PM
#2228   Who's in this? Risk on! eom ddbl_our_buck 06/03/16 07:59:37 AM
#2227   Adam F is well known and I'd guess diannedawn 01/15/16 04:20:13 PM
#2226   I'm unaware of the credibility of these writers MikeD248 01/15/16 12:29:52 PM
#2225   So was this a piece by Adam F? diannedawn 01/15/16 09:30:47 AM
#2224 MikeD248 01/13/16 03:10:44 PM
#2223   Link to the report? nick31 01/13/16 09:14:17 AM
#2222   Many thanks too. Future8Jerry 01/13/16 07:15:18 AM
#2221   Good stuff Mike. Minding 01/12/16 11:53:07 AM
#2220   It's down because of the report from MikeD248 01/12/16 10:36:05 AM
#2219   Sell the news? nick31 01/12/16 08:25:06 AM
#2218   My question was in reference to why BCLI Future8Jerry 01/12/16 12:11:07 AM